首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts--our experiences with CellPro, E rosetting and CliniMACS technique.
【24h】

Comparison of two different methods for CD34+ selection and T cell depletion in peripheral blood stem cell grafts--our experiences with CellPro, E rosetting and CliniMACS technique.

机译:两种不同的外周血干细胞移植中CD34 +选择和T细胞清除方法的比较-我们在CellPro,E rosetting和CliniMACS技术方面的经验。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to establish a suitable method for in vitro T cell depletion in peripheral blood stem cell grafts for mismatched/haploidentical transplantation in children and adults with severe hematological disorders and for autologous transplantation in patients with autoimmune diseases refractory to conventional immunosuppressive treatment. Two different selection techniques have been used: CD34+ selection using immunoaffinity columns (CellPro Ceprate) followed by T cell depletion by E-rosetting or CD34+ selection using submicroscopic paramagnetic beads (CliniMACS device) with T cell depletion in a one step procedure. The mean purity and recovery of CD34+ cells and efficiency of T cell removal in the final product were compared. From March 1995 to December 1998 we prepared twelve allografts using Cell Pro system for eight children with high-risk hematological malignancies and six autografts for six patients with severe autoimmune diseases. From January 1999 to October 2000 we prepared fifteen allografts using CliniMACS system for ten children with high-risk hematological diseases and inborn metabolic disorders or primary immunodeficiences, five allografts for three adult patients with high-risk hematological malignancies and two autografts for two patients with autoimmune diseases. In allogeneic transplantation the median purity of CD34+ cells in the final products after CellPro and E-rosetting was 85.6% (55.3%-95.7%); median recovery was 24.8% (17%-35%), median transplanted doses of T cells per kilogram of body weight were 0.66x10(4) (0-2.8); in autologous transplantation the median purity of CD34+ was 92.6% (55.6%-96%), median recovery was 28% (22%-46.2%), median transplanted doses of T cells per kilogram of body weight were 0.39x10(4) (0.0-3.6). After CliniMACS technique the median purity of CD34+ cells was 94.87% (69.15%-99%),medianrecoverywas 58% (30%-79.6%), median transplanted doses of T cells per kg of body weight were 0.254x10(4) (0-14.15); in autologous transplantation the median purity of CD34+ was 94% (94%-94%, median recovery was 97.4% (95%-99.8%), median transplanted doses of T cells per kilogram of body weight were 0.87x10(4) (0.49-1.24). We consider both methods of CD34+ selection and T cell depletion suitable for peripheral blood stem cell processing before mismatched hemopoietic stem cell transplantation in patients without identical donor or before autologous transplantation for severe autoimmune diseases. However, magnetic separation using CliniMACS system results in higher levels of purity and recovery with efficient T cell depletion.
机译:这项研究的目的是建立一种合适的方法,用于外周血干细胞移植物中的体外T细胞清除,用于严重血液学疾病的儿童和成人的错配/单倍移植,以及对于常规免疫抑制治疗难以治愈的自身免疫性疾病患者的自体移植。已经使用了两种不同的选择技术:使用免疫亲和柱(CellPro Ceprate)进行CD34 +选择,然后通过E-rosetting去除T细胞,或使用亚显微顺磁珠(CliniMACS装置)通过T细胞去除进行CD34 +选择。比较了最终产品中CD34 +细胞的平均纯度和回收率以及T细胞去除的效率。从1995年3月到1998年12月,我们使用Cell Pro系统为8名高危血液恶性肿瘤患儿准备了12例同种异体移植物,为6例患有严重自身免疫病的患者准备了6例同种异体移植物。从1999年1月到2000年10月,我们使用CliniMACS系统准备了15例同种异体移植物,用于10名高危血液病和先天性代谢紊乱或原发性免疫缺陷的儿童,5例同种异体移植物,供3名成人高危血液系统恶性肿瘤患者使用,2例同种异体移植物用于2例自身免疫性疾病患者疾病。在同种异体移植中,CellPro和E-rosetting后最终产品中CD34 +细胞的平均纯度为85.6%(55.3%-95.7%);中位数恢复率为24.8%(17%-35%),每公斤体重T细胞移植的中位数剂量为0.66x10(4)(0-2.8);自体移植中CD34 +的中位纯度为92.6%(55.6%-96%),中位回收率为28%(22%-46.2%),每公斤体重T细胞的中位移植剂量为0.39x10(4)( 0.0-3.6)。采用CliniMACS技术后,CD34 +细胞的中值纯度为94.87%(69.15%-99%),中值回收率为58%(30%-79.6%),每公斤体重T细胞的中值移植剂量为0.254x10(4)(0 -14.15);自体移植中CD34 +的中位纯度为94%(94%-94%,中位回收率为97.4%(95%-99.8%),每公斤体重T细胞的中位移植剂量为0.87x10(4)(0.49 -1.24)。我们认为CD34 +选择和T细胞清除的两种方法均适合于在没有相同供体的患者中错配造血干细胞移植之前或对于严重的自身免疫性疾病自体移植之前外周血干细胞的处理,但是,使用CliniMACS系统进行磁选的结果高效T细胞耗竭,可提高纯度和回收率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号